SRES-696-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S2076-2077; text: CR S2085-2086)
Sponsored by Rick Scott (R-FL)
What it does
This resolution expresses the Senate's support for designating April 2026 as "Parkinson's Awareness Month." It acknowledges facts about Parkinson's disease, recognizes patients, caregivers, researchers, and advocacy organizations, and reaffirms the Senate's general support for continued research into treatments and a cure. It does not appropriate funds, create programs, or impose any legal requirements.
Who benefits
The over 1 million Americans living with Parkinson's disease may benefit from increased public awareness. Advocacy and research organizations focused on Parkinson's disease gain a formal congressional endorsement. Family caregivers and loved ones of patients receive symbolic recognition. Clinical trial participants are specifically acknowledged. Researchers working on Parkinson's treatments may benefit from heightened public and institutional attention to the disease.
Who is hurt
No group is directly or materially harmed by this resolution. There are no mandates, spending changes, or regulatory effects. Competing disease advocacy communities receive no comparable recognition in this specific resolution, though this is a routine feature of single-disease awareness designations.
Supporters argue
Supporters argue that formal congressional recognition raises public awareness of a disease affecting over 1 million Americans — the fastest-growing neurodegenerative disease in the world — and helps direct attention toward the urgent need for better treatments and a cure. They contend that awareness designations can amplify the work of advocacy organizations, encourage clinical trial participation, and signal congressional commitment to continued research funding.
Opponents argue
Opponents argue that symbolic resolutions consume limited legislative floor time without producing measurable policy outcomes, and that awareness designations have no demonstrated effect on research funding levels or patient outcomes. They contend that Congress addresses dozens of such commemorative designations each session, potentially diluting their impact and substituting symbolic action for substantive legislation on healthcare research appropriations.